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A dynamic ribosomal biogenesis response is not
required for IGF-1–mediated hypertrophy of human
primary myotubes
Hannah Crossland,*,† James A. Timmons,* and Philip J. Atherton†,1
*Division of Genetics and Molecular Medicine, Guy’s Hospital, King’s College London, London, United Kingdom; and †School of Medicine,
Royal Derby Hospital, University of Nottingham, Derby, United Kingdom
ABSTRACT: Increased ribosomal DNA transcription has been proposed to limit muscle protein synthesis, making
ribosomebiogenesis central toskeletalmusclehypertrophy.Weexaminedthe relationshipbetweenribosomalRNA
(rRNA) production and IGF-1–mediated myotube hypertrophy in vitro. Primary skeletal myotubes were treated
with IGF-1 (50ng/ml)with orwithout 0.5mM/LCX-5461 (CX), an inhibitor ofRNApolymerase I.Myotubediameter,
total protein, andRNAandDNA levelsweremeasured alongwithmarkers ofRNApolymerase I regulatory factors
and regulators of protein synthesis. CX treatment reduced 45S pre-rRNA expression (2646 5% vs. IGF-1;P < 0.001)
and total RNA content (216 6 2% vs. IGF-1; P < 0.001) in IGF-1-treated myotubes. IGF-1-mediated increases in
myotube diameter (1.276 0.09-fold, P < 0.05 vs. control) and total protein (+206 2%; P < 0.001 vs. control) were not
prevented by CX treatment. Suppression of rRNA synthesis during IGF-1 treatment did not prevent early increases
inAKT (+2036 39% vs.CX;P < 0.001) and p70 S6K1 (2696 41% vs.CX;P < 0.001) phosphorylation. Despite robust
inhibition of the dynamic ribosomal biogenesis response to IGF-1, myotube diameter and protein accretion were
sustained. Thus, while ribosome biogenesis represents a potential site for the regulation of skeletal muscle protein
synthesis and muscle mass, it does not appear to be a prerequisite for IGF-1-induced myotube hypertrophy in
vitro.—Crossland, H., Timmons, J. A., Atherton, P. J. A dynamic ribosomal biogenesis response is not required for
IGF-1–mediated hypertrophy of human primary myotubes. FASEB J. 31, 000–000 (2017). www.fasebj.org
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Ribosomal biogenesis is a coordinated, multistep process
that plays a central biochemical role in cellular trans-
lational capacity andprotein synthesis (1–3). Transcription
of 45S pre–ribosomal DNA (rDNA) by RNApolymerase I
(Pol I) is considered a rate-limiting step in ribosomal bio-
genesis, which is in turn regulated by a number of key
factors including upstream binding factor (UBF) and the
selectivity factor 1 (SL1) complex, which are recruited at
the rDNA promoter (2). These events result in the activa-
tion of transcription initiation factor 1A (TIF1A), which
interacts with Pol I and enables initiation of Pol I–
dependent synthesis of 45S ribosomal RNA (rRNA). The
pre-rRNA 45S transcript is subsequently processed to
generate 3 mature rRNA subunits—28S, 18S, and 5.8S—
which assemble to formthemature ribosome, alongwith a
fourth rRNA transcribed by RNA Pol III (5S) and ;80
ribosomal proteins (1).
Two of the major regulators considered important for
ribosomal biogenesis are the mammalian target of rapa-
mycin (mTOR) C1 and c-Myc signaling pathways (3, 4).
Inhibition of mTORC1 by rapamycin was shown to in-
activate TIF1A and UBF (5, 6), indicating that mTORC1
plays a role in regulation of Pol I transcription. c-Myc has
been demonstrated to regulate UBF (7), as well as to di-
rectly regulate Pol I–dependent rRNA transcription
through binding to the promoter of rDNA (8), thus tran-
scribing a number of ribosomal protein genes (9). c-Myc,
initially described as a oncogene, has multiple actions,
including enhancing protein synthesis through transcrip-
tion of ribosomal protein RNA (9); it is regulated both
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transcriptionally and posttranscriptionally in muscle cells
in response to growth factors (10). Further, c-Myc has been
reported to increase after resistance exercise in animal
models and humans (11, 12), and c-Myc may act as a
regulator of the Pol I machinery (13) during human skel-
etal muscle hypertrophy.
Increased muscle protein synthesis (MPS) after re-
sistance exercise could be driven through increases in
translational efficiency (i.e., the rate of protein synthesis
per ribosome).Alternatively, resistance exercise could also
increase translational capacity (i.e., the amount of trans-
lational machinery per unit of cells per tissue), suggesting
that ribosomenumberwould then be a keydeterminant of
translational capacity. Indeed, several studies have re-
ported increases in markers of ribosomal biogenesis dur-
ing muscle hypertrophy (11, 14–16). These observations
imply that ribosomal biogenesis may represent a central
point for regulatingMPSandmusclemass, andthishas led
to the hypothesis that de novo ribosome biogenesis may
therefore be a prerequisite for skeletal muscle growth (17).
Whether de novo ribosome biogenesis is obligatory for
skeletal muscle growth or whether ribosome number de-
fines a maximum potential capacity for translation in
skeletal muscle is less clear. Studies have reported that in
vitro, serum-induced myotube hypertrophy (i.e., a com-
plex mix of growth factors, hormones, and nutrients) was
inhibited when rRNA induction was blocked using a
chemical inhibitor of Pol I (14), and that in C2C12 myo-
tubes, increases in protein content and MPS with high
serum stimulationwere prevented by Pol I inhibition (18).
These findings support an essential role for ribosomal
number inmuscle cellular growthwhen using thismurine
immortalized cell-line model of muscle biology, but
whether this holds true in human primary muscle cells is
not known. Therefore, the aim of the present study was:
1) to explore the role of ribosomal biogenesis in human
primary myocyte size regulation in vitro, 2) to determine
whether ribosomal biogenesis is required for skeletal
muscle hypertrophy in response to an established in vivo
trophic signal (IGF-1) (19–21), and 3) to identify the sig-
naling mediators driving these changes. We present a
comprehensive analysis of the impact of inhibition of ri-
bosome biogenesis using a specific chemical inhibitor of
RNA, Pol I, on factors linked to regulation of rDNA tran-
scription and protein turnover during hypertrophy.
MATERIALS AND METHODS
Primary cell culture and drug treatments
Human satellite cells were isolated from muscle biopsy samples
from healthy young adult donors (2 men and 1 woman), as pre-
viously described (22). This procedurewas approvedby the ethics
committee of the Karolinska Institutet (Stockholm, Sweden).
Briefly,musclebiopsysamplesweredigestedby incubating in5ml
TrypLEExpress (ThermoFisher Scientific,Waltham,MA,USA) at
37°C and 5% CO2, with stirring, for 20 min. Digestion was re-
peated twice, and isolated cells were recovered and maintained
in growth medium [DMEM/Nutrient Mixture F-12 (DMEM/
F-12); Thermo Fisher Scientific] containing 20% (v/v) fetal bo-
vine serum (Sigma-Aldrich, St. Louis, MO, USA), 1% (v/v)
antibiotic–antimycotic solution, and 4mML-glutamine (Thermo
Fisher Scientific). Enrichment of myogenic cells was achieved
using magnetic-activated cell sorting using anti-CD56 microbe-
ads, as previously described (22). Myoblast purity (assessed
through desmin immunofluorescent staining) was above 90% for
all 3 donors. Magnetic-activated cell–sorted myogenic precursor
cells were cultured on collagen-coated culture dishes in growth
media. Cells were maintained at 37°C with 5% CO2, and myo-
blasts were used for experimentation at passages 5 to 6.
When cells reached ;90% confluence, differentiation was ini-
tiated by changing themedium toDMEM/F-12 containing 2%
(v/v) horse serum (Sigma-Aldrich), with 4mML-glutamine and
1% (v/v) antibiotic–antimycotic solution (Thermo Fisher Scien-
tific). Six days after the induction of differentiation, the
medium was changed, and after 24 h, cells were treated with
IGF-1 (50 ng/ml) with or without 0.5 mM/L CX-5461 (CX;
Cayman Chemicals, Ann Arbor, MI, USA). All cells were
treated with 50 mM/L cytosine arabinoside (Sigma-Aldrich)
to reduce proliferation of nondifferentiated myoblasts. The
dose of CX was chosen on the basis of preliminary experi-
ments, whereby doses at 1 mM/L and above caused significant
declines in total DNA after 24 h, while doses below 0.25 mM/L
did not reduce total RNA content after 24 h (data not shown).
Samples were collected after 4 or 24 h of treatment. Samples
were collected in Trizol (Thermo Fisher Scientific) for RNA iso-
lation, homogenization buffer (50 mM Tris-HCl, pH7.5, 1 mM
EDTA, 1 mM EGTA, 10 mM b-glycerophosphate, 50 mM NaF),
and complete protease inhibitor cocktail tablet (Roche, Basel,
Switzerland) for protein extraction, or 0.3 M/L NaOH for total
protein, RNA, and DNA extraction and quantification. In-
dependent experiments were carried out for each donor (n = 3–4
well replicates for each treatment group). Lightmicroscope images
of myotubes were also taken after experimentation for measure-
ment of myotube diameter. Mean diameter was calculated from
measurementof200myotubesacross10 images foreach treatment.
Immunofluorescent staining
After experimentation, cells werewashed in PBS and fixed using
ice-cold 1:1 acetone:methanol. After fixation, cells were washed
in PBS and incubated in 5% (v/v) goat serum for 30min at room
temperature. Cells were then incubated in rabbit anti-desmin
monoclonal antibody (Abcam, Cambridge, MA, USA) for 1 h at
room temperature, and after further washing were incubated
with anti-rabbit FITC-conjugated secondary antibody (Abcam).
After washing with PBS, cells were mounted and stained with
DAPI using Fluoroshieldmountingmediumwith DAPI. Images
were used for assessment of nuclei per myotube.
Total protein, RNA, and DNA measurements
After experimentation, cells were collected in 0.3 M/L NaOH,
and samples were incubated at 37°C for 20 min for extraction of
total alkaline-solubleprotein.After proteinquantification, 1M/L
perchloric acid was added to the samples, and samples were left
at 4°C for 30 min. After centrifugation, the supernatant was
quantified for RNA. To the pellet, 2 M/L perchloric acid was
added, and samples were incubated at 70°C for 1 h. The super-
natant was used for total DNA quantification.
RNA extraction, cDNA synthesis, and real-time PCR
RNA was isolated using Trizol reagent (Thermo Fisher Sci-
entific) according to the manufacturer’s instructions. After
extraction, RNA was resuspended in 20 ml of RNase-free
water, and quantity and quality were determined by a
NanoDrop 2000 (Thermo Fisher Scientific). cDNA was syn-
thesized by reverse transcription using the High Capacity
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cDNA synthesis kit (Thermo Fisher Scientific) with 500 ng
RNA. Samples were diluted 1:10 with RNase-free water after
cDNA synthesis, and real-time PCR was performed using 1
ml cDNA in duplicate and 6 ml master mix containing SYBR
Select Master Mix (Thermo Fisher Scientific) and primers
targeting the following genes: 45S pre-rRNA (designed to
target the 59 external transcribed spacer), 28S rRNA, 5.8S
rRNA (designed to span the 5.8S and 59 internal transcribed
spacer region), polymerase 1 subunit (POLR1) A, POLR1B,
POLR1C, POLR1E, UBF, TIF1A, c-MYC, TATA-box binding
protein associated factor, RNA polymerase I, A (TAF1A),
ribosomal protein (RP) L13A, RPL32, RPS5, and RPS19
(Supplemental Table 1). Samples were analyzed using a Viia
7 real-time PCR machine (Thermo Fisher Scientific) with the
following thermal cycling conditions: 2 min at 50°C, 10 min
at 95°C, and 40 cycles of 15 s at 95°C and 1 min at 60°C. 18S
rRNA was used for normalization because it did not differ
between treatment groups. The DCt method (23) was used to
calculate relative changes in target mRNA abundance.
Protein extraction and Western blot analysis
Cell protein extracts were prepared by repeatedly passing
samples through gel-loading pipette tips. Samples were
centrifuged at 13,000 g for 10 min at 4°C, and lysates (5 mg
protein) were loaded onto Criterion XT 12% Bis-Tris gels
(Bio-Rad, Hercules, CA, USA) at 200 V for 1 h. Samples were
transferred to PVDF membrane at 100 V for 1 h, and mem-
branes were blocked using 2.5% (w/v) bovine serum albu-
min for 1 h at room temperature. After this, membraneswere
incubated overnight at 4°C with the following primary an-
tibodies (all diluted 1:2000): phosphorylated mTOR Ser2448
(5536), total mTOR (2983), phosphorylated p70 S6K1 Thr389
(9234), total p70 S6K1 (9202), phosphorylated AKT Ser473
(4060), total AKT (4685), phosphorylated 4E-BP1 Thr37/46
(2855), total 4E-BP1 (9452), total c-Myc (13987), phosphor-
ylated retinoblastoma (Rb) Ser780 (3590), total TIF1A
(ab57994), phosphorylated UBF Ser484 (ab182583), total
UBF (ab75781), phosphorylated forkhead box O 3a
(FOXO3a) Ser253 (13129), muscle RING finger 1 (MuRF1)
(MP3401), light chain 3B (LC3B; 2775), and ubiquitin (3933).
All antibodies were purchased from Cell Signaling Tech-
nology (Danvers, MA, USA) except for TIF1A, phospho-
UBF, and total UBF, which were purchased from Abcam,
and MuRF1, which was purchased from ECM Biosciences
(Versailles, KY, USA). After incubation with primary anti-
body, membranes were washed for 3 times 5 min with Tris-
buffered saline–Tween, then incubated for 1 h at room
temperature with horseradish peroxidase–conjugated sec-
ondary antibody (all anti-rabbit except for TIF1A, which
was anti-mouse; New England Biolabs, Ipswich, MA, USA),
diluted 1:2000. Bands were visualized using enhanced
chemiluminescence detection reagent (EMD Millipore,
Billerica, MA, USA) and a Chemidoc XRS imaging system
(Bio-Rad). Coomassie Brilliant Blue staining of the mem-
brane was used for normalization against total protein
loading.
Statistical analyses
Data were analyzed by 1-way ANOVA, with Tukey’s multiple
comparison test used to examine differences between treatment
groups. For the real-time PCR data, 2-way ANOVA with
Tukey’s multiple comparison test was used to examine differ-
ences between groups. All data are presented as means 6 SEM,
with P, 0.05 being considered statistically significant. All data
were analyzed using GraphPad Prism v.6 (La Jolla, CA, USA).
RESULTS
Myotube diameter and nuclei per myotube
Treatment of differentiated myotubes for 24 h with CX did
not affect myotube diameter (Fig. 1A, B). IGF-1 caused an
increase inmyotube diameter (1.276 0.09-fold, P, 0.05 vs.
control), and in the presence of CX and IGF-1, myotube
diameter was higher than with CX alone (1.256 0.08-fold,
P,0.05vs.CX;Fig.1A,B).Thenumberofnucleipermyotube
(assessedbydesmin immunofluorescence)wasnodifferent
between CX-treated and untreated cells (Fig. 1C, D), but
with IGF-1 therewasan increase in thenumberofnucleiper
myotube after 24 h (4.76 0.34 with IGF-1, 4.16 0.35 with
control; P, 0.05 vs. control). CX did not prevent the IGF-1-
induced increase in number of nuclei per myotube (4.7 6
0.35 with CX + IGF-1; P, 0.05 vs. CX; Fig. 1C, D).
Pol I specificity and total protein, RNA, and
DNA measurements
A dose–time course of CX treatment in myotubes was un-
dertaken to verify specificity of the compound for RNAPol I
vs.RNAPol II.At2, 4, and24h,CXcauseda reduction in45S
rRNAexpression relative to untreated controls (for 0.25mM:
28062%vs.controlat2h;P,0.001,27561%vs.controlat
4 h; P, 0.001,2566 7% vs. control at 24 h; P, 0.001, for
0.5mM:2866 3% vs. control at 2 h;P, 0.001,2836 1% vs.
control at 4 h; P, 0.001,2596 6% vs. control at 24 h; P,
0.001; Fig. 2A). Expression of c-Myc (used to assess Pol II
transcription)wasalteredbyCXtreatmentwith0.5mMat2h
(23768%vs. control;P,0.05) andbothdosesat4h (2426
8% vs. control;P, 0.01 at 0.25mM, 446 2% vs. control; P,
0.01at 0.5mM;Fig. 2B).Nevertheless, agreaterpreference for
inhibition of RNA Pol I than RNA Pol II was observedwith
CX treatment. Total protein and DNA per well was not
altered byCXalone (Fig. 2C, E), but after 24 h, total RNA
(215 6 2% vs. control; P , 0.001; Fig. 2D) and the RNA/
DNA ratio (2146 3% vs. control; P, 0.05) were lower. CX
alsocausedareduction intheRNA/proteinratioat24h(215
6 2% vs. control; P, 0.01; Fig. 2H). IGF-1 treatment for 24 h
resulted in higher total protein (+20 6 2%; P , 0.001 vs.
control; Fig. 2C), total RNA (+2363%;P, 0.001 vs. control;
Fig. 2D), and RNA/DNA ratio (+21 6 4%; P , 0.05 vs.
control; Fig. 2G). There was no change in total DNA or the
protein/DNA ratio with IGF-1 treatment (Fig. 2E, F). The
increase in total RNA andRNA/DNA ratiowith IGF-1was
lowerwithCXtreatment (P,0.001vs. IGF-1;Fig.2BandP,
0.01 vs. IGF-1; Fig. 2G), but the increase in total protein with
IGF-1 was not prevented by the addition of CX (Fig. 2C).
mRNA expression
Expression of 45S rRNAwas significantly reduced by CX
treatmentbothwithandwithout IGF-1after 4h (27264%
vs. control; P , 0.001 with CX, 264 6 5% vs. IGF-1; P ,
0.001withCX+ IGF-1) and24h (2446 5% vs. control;P,
0.01 with CX, 2486 11% vs. IGF-1; P, 0.001 with CX +
IGF-1; Fig. 3A), and 5.8S expression showed a similar
pattern of changes (Fig. 3B). Expression of 28S was
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unaffected by treatments except for at 24 h, where CX
treatment with or without IGF-1 caused a reduction in
expression of 28S relative to untreated controls (2536 6%
vs. control; P, 0.001with CX,2346 15% vs. control; P,
0.05 with CX + IGF-1; Fig. 3C).
Expression of c-Myc mRNA was lower with CX at 4 h
(2336 4% vs. control; P, 0.05; Fig. 3D), but it returned to
baseline levels by 24 h. IGF-1 caused an increase in c-Myc
mRNAat both time points (+516 12% vs. control at 4 h;P,
0.01; +476 11% vs. control at 24 h; P, 0.001; Fig. 3D). Ad-
dition of CX to IGF-1-treated cells did not affect c-Myc ex-
pression compared to IGF-1 alone at 4 h, but its expression
was significantly lower compared to the IGF-1 group at 24 h
(P, 0.001 vs. IGF-1; Fig. 3D). UBFmRNAwas increased by
CXtreatmentat24h(+2866%vs.control;P,0.05),andIGF-1
alone increased UBFmRNA at both time points (+536 11%
vs. control at 4 h;P, 0.001; +56611% vs. control at 24 h;P,
0.001; Fig. 3E). Addition of CX to IGF-1-treated cells did not
prevent this increase at either time point, although at 24 h,
there was no difference in UBF expression between the CX
andCX+IGF-1group,butmRNAlevelswereelevatedabove
control (+416 8% vs. control; P, 0.001; Fig. 3E). Expression
of TIF1A mRNAwas higher with CX at 24 h (+336 8% vs.
control; P, 0.05; Fig. 3F). IGF-1 caused an increase in TIF1A
mRNAat both time points (+77612% vs. control at 4 h; P,
0.001; +3768% vs. control at 24 h;P, 0.05; Fig. 3F), and this
increasewas not affected by the addition of CX at either time
point. Similar patterns of change inmRNAexpression across
treatments were observed for TAF1A (Fig. 3G).
Expression of RNA Pol I subunit POLR1A was higher
with CX treatment after 24 h (+39 6 9% vs. control; P ,
0.05; Fig. 4A), andwith IGF-1 at 4 h (+476 11% vs. control;
P, 0.001) and 24 h (+356 8% vs. control; P, 0.001; Fig.
4A). When CX was added to IGF-1-treated cells, expres-
sion of POLR1A was similar to IGF-1 alone (+416 8% vs.
CXat 4h;P, 0.001,+476 16% vs. control at 24h;P, 0.01;
Fig. 4A). Similar patterns in expression changes were ob-
served for POLR1B (Fig. 4B), POLR1C (Fig. 4C), and
POLR1E (Fig. 4D), except that for POLR1E, at 24 h, there
was no change in expression after CX or CX + IGF-1
treatment relative to the control group. Ribosomal protein
geneRPL13AmRNAwasunaffectedacrossgroups except
at 4 h, where RPL13A was higher with IGF-1 and CX +
IGF-1 (+366 7% vs. control; P, 0.001; +276 7% vs. CX;
Figure 1. Images of human myotubes (A), myotube diameter measurements (B), nuclei per myotube (C), and desmin staining of
myotubes (D) after 24 h of IGF-1 with or without CX treatment. Light microscope images were taken from differentiated
myotubes after 24 h of 50 ng/ml IGF-1 treatment with or without 0.5 mM CX. Human primary myotubes were stained by
immunoﬂuorescence for desmin after incubation for 24 h with IGF-1 and/or CX. Number of nuclei per myotube was calculated
for each group.
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P, 0.01, respectively; Fig. 4E). RPL32 expression was un-
affected by CX alone but was elevated by IGF-1 at 4 h
(+506 10% vs. control; P, 0.001) and 24 h (+986 10% vs.
control; P , 0.001; Fig. 4F). With CX + IGF-1, RPL32 ex-
pression was increased relative to the CX group at 4 h
(+226 6% vs.CX; P, 0.05) but was significantly lower com-
pared to IGF-1 alone, and at 24 h, expression levels were
significantly lower compared to IGF-1 (Fig. 4F). Expres-
sion of RPS5 was unchanged across treatments at either
time point, except for at 4 h, where RPS5 mRNA was in-
creased by IGF-1 (+266 10% vs. control; P, 0.05; Fig. 4G).
RPS19was unaffected by CX alone at either time point but
was increased by IGF-1 at 4 h (+28 6 8% vs. control; P ,
0.05) and 24 h (+54 6 8% vs. control; P , 0.001; Fig. 4H).
Addition of CX to IGF-1-treated cells did not prevent the
increase in RPS19 at 4 h, but at 24 h, the increase observed
with IGF-1 alone was completely prevented by CX (P ,
0.001 vs. IGF-1; Fig. 4H).
Protein expression and phosphorylation
Acute changes in anabolic-related signaling proteins were
measured after 4 h of IGF-1 treatment with and without
Figure 2. Dose–time course of CX treatment and total protein, RNA, and DNA content in human primary myotubes after IGF-1
treatment with or without CX. Expression of 45S rRNA (A) and c-Myc (B) mRNA was measured in human primary myotubes after
2, 4, and 24 h of CX treatment (0.25 or 0.5 mM). Total protein (C), RNA (D), and DNA (E) were measured in human
primary myotubes after 24 h of IGF-1 (50 ng/ml) treatment with or without 0.5 mM CX. From these values, the protein/
DNA (F), RNA/DNA (G) and RNA/protein (H) ratios were calculated. Data are expressed as means 6 SEM from 3 independent
experiments (n = 4–6 replicates per treatment). *P, 0.05; **P, 0.01; ***P, 0.001 vs. untreated control, respectively; ###P, 0.001 vs.
CX; ††P , 0.01; †††P , 0.001 vs. IGF-1.
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CX. Treatment of myotubes with CX alone did not affect
mTOR Ser2448 phosphorylation or total mTOR protein at
4 h, and so there was no change in phospho-total mTOR
(Fig. 5A, C). With IGF-1 treatment, mTOR Ser2448 phos-
phorylation, normalized to total mTOR (which was un-
changed across all treatments; data not shown), was
higher relative to untreated controls (+74 6 16% vs. con-
trol;P, 0.001; Fig. 5A,C). Phospho-totalmTORwithCX+
IGF-1 treatmentwas elevated aboveCX alone (+546 14%
vs.CX;P, 0.05) butwasnodifferent from the IGF-1 group
(Fig. 5A, C). Expression of phosphorylated p70 S6K1
Thr389 and total p70 S6K1 was unaffected by CX treat-
ment at 4h (Fig. 5A,D),whereas IGF-1 treatment increased
phospho-totalp70S6K1 (+252660%vs. control;P,0.001;
Fig. 5A, D). Addition of CX to IGF-1-treated cells did not
affect the increase in p70 S6K1 phosphorylation (Fig. 5A,
D). Treatment with CX did not affect phosphorylated
(Ser473) or total AKT (Fig. 5B, E), but after 4 h of IGF-1
treatment, phospho-total AKT was higher relative to
control (+191 6 44% vs. control; P , 0.001; Fig. 5B, E).
Addition of CX to IGF-1-treated cells did not prevent this
increase (Fig. 5B, E; +203 6 39% vs. CX; P , 0.001). Total
AKT was unaffected across treatments (data not shown).
Phosphorylated (Thr37/46) or total 4E-BP1 were un-
affectedbyeitherCXalone, IGF-1, orCX+ IGF-1 treatment
(Fig. 5B, F).
Protein expression and/or phosphorylation of se-
lected regulators of ribosome biogenesiswere assessed
after IGF-1 and CX treatments. Expression of total
c-Myc was lower with CX treatment (233 6 9% vs.
control; P, 0.05; Fig. 6A, B), whereas IGF-1 caused an
increase in total c-Myc (+359 6 133% vs. control; P ,
0.001). Addition of CX to IGF-1-treated cells did not
prevent the increase in c-Mycwith IGF-1 (+5576 140%
vs. CX; P , 0.001; Fig. 6A, B). Phosphorylation of Rb
(Ser780) was unchanged with CX treatment but higher
with IGF-1 (+596 15% vs. control at 4 h; P, 0.01; Fig.
6A, C). CX did not prevent the increase in Rb phos-
phorylation in IGF-1-treated cells (+30 6 9% vs. CX;
P , 0.05). Total TIF1A protein was not affected by CX
Figure 3. Expression of rRNA and Pol I regulatory factors after IGF-1 treatment with or without CX. Expression of 45S (A), 5.8S
(B), 28S (C), c-Myc (D), UBF (E), TIF1A (F), and TAF1A (G) after 4 and 24 h of IGF-1 treatment (50 ng/ml) with or without
0.5 mM CX in human primary myotubes. Data are normalized to 18S expression and are expressed as means 6 SEM from
3 independent experiments (n = 4 replicates per treatment). *P , 0.05; **P , 0.01; ***P , 0.001 vs. untreated control,
respectively. ##P , 0.01; ###P , 0.001 vs. CX, respectively; †††P , 0.001 vs. IGF-1.
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treatment, while IGF-1 increased TIF1A protein at 4 h
(+140 6 34% vs. control; P , 0.001; Fig. 6A, D). TIF1A
protein was significantly higher after CX + IGF-1
treatment (+186 6 43% vs. CX; P , 0.001). CX had no
effect on expression of phosphorylated (Ser388) or to-
tal UBF (Fig. 6A, E), whereas phospho-total UBF was
higher with IGF-1 treatment (+38 6 12% vs. control;
P , 0.05). This increase was not prevented by addition
of CX (+24 6 12% vs. CX; P , 0.05).
Markers of muscle protein breakdown were mea-
sured to assess whether IGF-1-mediated changes in
protein degradation were impacted by the inhibition of
ribosome biogenesis. Phosphorylation of FOXO3a
(Ser253) was unchanged with CX alone but was in-
creasedby IGF-1 (+4369%vs. control;P, 0.01) andCX+
IGF-1 (+49 6 7% vs. CX; P , 0.01; Fig. 7A, C). Total
MuRF1 protein was unaltered by CX or IGF-1 treat-
ments (Fig. 7A, D). Autophagymarker LC3B, presented
as the ratio of LC3II/I, was lowerwith IGF-1 (2726 4%
vs. control; P , 0.001; Fig. 7A, E), and this was not al-
tered by the addition ofCX to IGF-1-treated cells (2736
4% vs. CX; P , 0.001; Fig. 7A, E). Finally, levels of
ubiquitinated proteins, determined by measuring in-
tensity of the entire lane, were unaffected by CX (Fig.
7B, F) but were lower with 4 h of IGF-1 (220 6 5% vs.
control; P , 0.05; Fig. 7B, F) and CX + IGF-1 treatment
(218 6 2% vs. control; P , 0.05; Fig. 7B, F).
DISCUSSION
A growing number of studies have provided various
levels of evidence that rDNA transcription represents a
crucial event before successful muscle hypertrophy, in-
dicating that de novo ribosome biogenesis may be neces-
sary for muscle growth (11, 13, 14, 16, 17). For example, in
Figure 4. mRNA expression of RNA Pol I subunits and ribosomal protein genes after IGF-1 treatment with or without CX.
Expression of POLR1A (A), POLR1B (B), POLR1C (C), POLR1E (D), RPL13A (E), RPL32 (F), RPS5 (G), and RPS19 (H)
mRNA after 4 and 24 h of IGF-1 treatment (50 ng/ml) with or without 0.5 mM CX in human primary myotubes. Data are
normalized to 18S expression and expressed as means 6 SEM from 3 independent experiments (n = 4 replicates per treatment).
*P , 0.05; **P , 0.01; ***P , 0.001 vs. untreated control, respectively. #P , 0.05; ##P , 0.01; ###P , 0.001 vs. CX, respectively;
†P , 0.05; †††P , 0.001 vs. IGF-1, respectively.
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mice, increases in muscle rRNA content, rDNA tran-
scription, and expression of Pol I–related genes were ob-
served at the onset of hypertrophy after synergist ablation
(13). Furthermore, in a rodent synergist ablation model,
where partial removal of synergist muscles allowed dif-
ferent magnitudes of compensatory hypertrophy, in-
creases in rRNA content showed a strong correlationwith
relativemuscleweight after overload (16).However, there
are several methodologic considerations that must be
taken into account when interpretation these data. For
example, there are concerns that the early changes in the
synergist ablation model are partly related to edema and
nonmuscle cellular infiltration (24–26), and this could
feasibly influence muscle wet weight and total DNA
content; it could also alter the total RNA and mRNA
profile. The reported very high correlation (r = 0.93) be-
tween rRNA content and growth (16) reflected the re-
gressionanalysisusing thegroupmeanvalues (rather than
raw data), thus elevating the strength of the linear associ-
ation. A similar problem arises when the relationship be-
tween anabolic genes and growth is plotted across, rather
than with, independent muscle types (27).
In healthy young men, increases in key ribosome bio-
genesis regulatory factors were observed after acute re-
sistance exercise both before and after training, with
increases in muscle rRNA observed after training (15).
However, no change in total muscle RNA was observed
after resistance training, and the reported4-fold increase in
18S seems implausible given it only approximates total
RNA, while ;90% of total RNA is rRNA. Recent work
from this laboratory has provided evidence that deficits in
both MPS and RNA synthesis underlie blunted hyper-
trophic responses to exercise with aging in humans (11).
Here, RNAwasmeasured from freeze-driedmusclemass.
RNA content increased with resistance training only in
young individuals. Nevertheless, no study has presented
conclusive evidence that ribosomal biogenesis is a pre-
requisite for skeletal muscle hypertrophy. Indeed, in the
current study, we observed that inhibition of ribosomal
biogenesis did not prevent early activation of anabolic
signaling factors (i.e., mTOR, p70 S6K1, AKT). Further-
more, inhibition of rRNA synthesis did not prevent
IGF-1-mediated increases in myotube diameter and
protein accretion. Thus, myotube hypertrophy in vitro
could occur despite inhibition of rRNA synthesis.
Our initial experiments confirmed effective inhibi-
tion of Pol I activity occurred after treatment with CX,
bothwith andwithout the addition of IGF-1, as assessed
by measurement of pre-rRNA expression. There was
also some evidence of inhibition of Pol II–dependent
transcription with CX treatment because c-Myc was
suppressed after 4 h treatment. However, other genes
measured in the studywere unaffected by CX treatment,
suggesting thatCXwas not generally targetingPol II and
that c-Mycwas probably indirectly influenced as a result
of Pol I inhibition. However, we acknowledge that use of
a single pharmacologic agent to inhibit ribosome biogenesis
is a limitation of our study, and that additional pharma-
cologic compounds targeting Pol I and/or gene knock-
downof regulatory componentswould support themajor
findings of this study. Gene expression analysis revealed
that IGF-1 caused up-regulation of several subunits of Pol I,
Figure 5. Protein expression and phosphorylation of selected mTOR signaling components in human primary myotubes after
IGF-1 treatment with or without CX. A, B) Representative blots from Western blot analysis of selected signaling targets taken from
differentiated myotubes after 4 h of IGF-1 treatment with or without CX. C–F) Relative changes in phosphorylated (phospho)-
total mTOR, phospho-total p70 S6K1, phospho-total AKT, and phospho-total 4E-BP1 after IGF-1 treatment with or without
CX. RAU, relative arbitrary units. Data are presented as means 6 SEM from 3 independent experiments (n = 3 per treatment).
*P , 0.05; **P , 0.01; ***P , 0.001 vs. control, respectively; #P , 0.05; ###P , 0.001 vs. CX, respectively.
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highlighting one mechanism linking early activation of
IGF-1-induced factors and increases in translational ca-
pacity. Increases in POLR1A, POLR1B, and POLR1C ex-
pression were also observed by 24 h with CX treatment
alone, possibly indicating attempts to increases Pol I
abundance in the face of inhibition of Pol I–dependent
transcriptional activity. Conversely, POLR1E mRNA ex-
pressionwasnot increasedafterPol I inhibitionat24hand
was significantly reduced in CX + IGF-1–treated myo-
tubes. POLR1E encodes a Pol I elongation factor that in
yeast has been shown to be important for regulating the
recruitment and release of TIF1A during rDNA tran-
scription (28, 29). Of the Pol I subunits measured in this
study, onlyPOLR1Edoes not have a counterpart in thePol
II or Pol III complexes (30), and they thusmaybe regulated
in a different manner than the other subunits. As with the
Pol I subunits, the expression of ribosomal protein genes
showed differential regulation by IGF-1 and with Pol I
inhibition. For example, while RPS5 and RPL13A were
largely unaffected by IGF-1 or CX treatment, both RPL32
and RPS19weremarkedly up-regulated by IGF-1, and by
24 h, these increases were completely prevented by Pol I
inhibition.
Increased expression of ribosomal protein genes has
been associated with increased cellular growth, and there
is evidence that c-Mycmayup-regulate ribosomalproteins
(9, 31) via the mTOR pathway (32). The present observa-
tions imply that ribosomal protein genes can in fact be
regulated by a variety of upstream factors, potentially
reflecting c-Myc-dependent and -independent regulatory
pathways. Examination of Pol I regulatory factors showed
that IGF-1 induced early (4 h) increases in c-Myc aswell as
UBF, TIF1A, and TAF1A, all of which play a crucial role in
Pol I preinitiation complex assembly and rDNA tran-
scription. During the early stages of Pol I–dependent
transcription, binding of UBF to the rDNA promotor al-
lows recruitment of the SL1 complex, ofwhich TAF1A is a
part (1, 2). TIF1A interacts directly with Pol I and is es-
sential for mediating the interaction of Pol I and SL1 to
form the preinitiation complex at the rDNA promoter (1,
2). Inhibition of Pol I didnotprevent earlyup-regulationof
these factors, and while at 24 h the up-regulation of UBF,
TIF1A, and TAF1A by IGF-1 was not affected by CX,
c-Mycwas significantly reduced compared to IGF-1 alone.
The patterns of change in expression of UBF, TIF1A, and
TAF1A suggest they may be regulated by a common up-
stream factor, but because c-Myc expression appeared to
be suppressed at this time point, it could potentially occur
independently of c-Myc.
It has been reported that serum-induced growth of
humanmyotubes was completely prevented when rRNA
synthesis was inhibited with CX (14). In a separate study,
Pol I inhibition blocked increases in protein content and
MPS with high serum stimulation in C2C12 myotubes,
where it was demonstrated that mTOR signaling plays a
direct role in rDNA transcription in the early phases of
musclehypertrophy (18). In agreementwith apositive role
for ribosomal biogenesis for in vivo muscle mass regula-
tion,work fromour laboratoryhasdemonstrated that age-
related deficits in anabolic responses to exercise include
impaired ribosomal biogenesis (11). Thus, the findings of
the present study, where increases in both myotube
Figure 6. Protein expression and phosphorylation of selected regulators of ribosome biogenesis in human primary myotubes after
IGF-1 treatment with or without CX. A) Representative blots from Western blot analysis of selected signaling targets taken from
differentiated myotubes after 4 h of IGF-1 treatment with or without CX. B–E) Relative changes in total c-Myc, phosphorylated Rb
Ser780, total TIF1A, and phospho-total UBF after IGF-1 treatment with or without CX. RAU, relative arbitrary units. Data are
presented as means 6 SEM from 3 independent experiments (n = 3 per treatment). *P , 0.05; ***P , 0.001 vs. control,
respectively; #P , 0.05; ###P , 0.001 vs. CX, respectively.
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diameter and protein accretionwith IGF-1 treatmentwere
not prevented byCX,were unexpected.While it is unclear
why such differences were observed between the various
cell-based studies, this could reflect the differing growth
stimulus used; for example, use of 20% serum provides a
battery of hormones and growth factors, triggering mul-
tiple pathways to growth in comparison with our use of
only IGF-1. Thus, using IGF-1 alone, we were evaluating
solely IGF-1-specific effects onmuscle growth, rather than
high serum (fetal bovine serum), which contains a wide
composition and variable quantity of growth factors (in-
cluding embryonic), hormones, and nutrients. Addition-
ally, other cell- or experimental-relateddifferences (e.g., the
dose of CX used—previous studies used a 2-fold higher
dose than in the present study—cell species, donor char-
acteristics, and stage of differentiation at which experi-
ments were performed) could feasibly have accounted for
the differences observed.
It is well established that the mTORC1 signaling path-
way is an important regulator of translational efficiency
(i.e., protein synthesis rates) and translational capacity
in skeletal muscle (3). Activation of mTORC1 stimulates
formation of the Pol I transcription complex via UBF
phosphorylation (2), but it has also been linked to the
control of ribosome biogenesis through Pol II– and
Pol III–dependent mechanisms (3). Conversely, mTOR-
independent mechanisms have been described for
growth-related changes in regulation of ribosome bio-
genesis, with rapamycin-insensitive changes in UBF
phosphorylation and c-Myc observed after electrical
stimulation in rats (33). In the present study, blocking
rRNA synthesis did not prevent the acute IGF-1-mediated
increases in anabolic signaling components (phospho-
total mTOR, p70 S6K1, AKT), indicating the early
increases in translational efficiency with IGF-1 did not re-
quire de novo ribosome biogenesis. Evaluation of Pol I
regulatory factors showed that IGF-1 robustly increased
phosphorylation of UBF and total protein levels of TIF1A
and c-Myc at 4 h. These findings are consistent with pre-
vious studies showing stimulation of ribosomal regulatory
factors with growth stimuli (13, 15, 34), and they confirm
that anabolic stimuli play a crucial role in increasing
translational capacity through Pol I–dependent rDNA
transcription. More work is required to fully elucidate the
specific pathways involved in activation of the factors re-
quired for increased protein synthesis.
We also evaluated the impact of inhibition of ribosomal
biogenesis on IGF-1-mediated changes in markers of
muscle protein breakdown. Inhibition of ubiquitin-
dependent protein breakdown is thought to occur in
part via AKT-mediated phosphorylation of FOXO tran-
scription factors, which leads to down-regulation of E3
ubiquitin ligases muscle atrophy F-box (MAFbx) and
MuRF1 (35–37). We found that IGF-1-mediated increases
in FOXO3a phosphorylation were not prevented by Pol I
inhibition, although MuRF1 protein levels were un-
changed across treatments. This corresponded with a re-
duction in levels of ubiquitinated protein in both the IGF-1
and CX + IGF-1 groups. Although protein ubiquitination
is required for many biologic processes, these findings
Figure 7. Protein expression and phosphorylation of selected regulators of protein breakdown in human primary myotubes after
IGF-1 treatment with or without CX. A, B) Representative blots from Western blot analysis of selected signaling targets taken from
differentiated myotubes after 4 h of IGF-1 treatment with or without CX. C–F) Relative changes in phosphorylated FOXO3
Ser253, total MuRF1, LC3II/LC3I ratio, and ubiquitinated proteins after IGF-1 treatment with or without CX. RAU, relative
arbitrary units. Data are presented as means 6 SEM from 3 independent experiments (n = 3 per treatment). *P , 0.05; **P ,
0.01; ***P , 0.001 vs. control, respectively. #P , 0.05; ##P , 0.01; ###P , 0.001 vs. CX, respectively.
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might indicate that IGF-1-mediated reduction in protein
breakdownwas not affected by the inhibition of ribosome
biogenesis. FOXO3ahas alsobeen implicated in regulation
of autophagic-lysosomal catabolic processes, partly via
transcription of the autophagy protein LC3B (38, 39),
whereby conversion of the form LC3I to LC3II is used as a
marker of autophagy. IGF-1 treatment resulted in a re-
duction in the LC3II/I ratio, and this was no different in
the presence of CX, although it should be noted that the
reduced LC3II/I ratio was due to an increase in LC3I
rather than a reduction in LC3II. Overall, these findings
suggest that the changes inmuscleproteinbreakdownand
autophagy after IGF-1 treatment were not affected by in-
hibition of rRNA synthesis.
Recent studies have investigated downstreameffects of
CX in relation to its antiproliferative and apoptotic prop-
erties, with one study reporting that CX caused DNA
damage and apoptotic cell death in various cancer cell
lines (40). However, CX has been reported to exert apo-
ptotic effects specificallyoncancer cell andnotnormal cells
in vivo (41), suggesting that different cells types show dif-
ferent sensitivities to the compound. Previous work using
CX with skeletal muscle cells used similar doses to our
studywith no reported effects on cell viability (14, 18), and
in the present study, 24 h of treatment with CX alone
caused no changes in total protein or DNA content, sug-
gesting that the dose and duration of treatment did not
cause adverse effects related to cell viability. It has also
been demonstrated that CX treatment for 72 h induced
autophagy and altered mTOR signaling in osteosarcoma
cell lines (42). While in the present study treatment with
CX alone did not appear to influence mTOR-related sig-
naling, it should be acknowledged that longer-term
treatment with the compound might have induced ad-
verse effects related to mTOR inhibition and autophagy.
In summary, this study demonstrated that growth
factor–mediated myotube hypertrophy, as assessed by
increases inmyotube diameter and protein accretion, does
not require activation of rRNA synthesis. While ribosome
biogenesis still represents a central component of skeletal
muscle mass, the present findings imply that there does
not appear to be a prerequisite for de novo ribosome syn-
thesis in enablingmuscle cell growth in response to IGF-1.
It is important to acknowledge the limitations of using an
in vitro model to study processes related to muscle mass
regulation and ribosomal biogenesis. This is similar to
synergist ablationmodels used to study the role of satellite
cells or ribosomal biogenesis inmuscle growth,which can
offer some mechanistic insight but have limited use for
understanding physiologic muscle growth in vivo. While
we focused on myotube hypertrophy after 24 h of IGF-1
treatment, future experiments incorporating longer-term
treatments could feasibly identify a point at which sup-
pression of ribosome biogenesis does become limiting for
continued myotube growth. Thus, future work should
focus on understanding the roles of translational capacity
and efficiency in the regulation of muscle hypertrophy,
including use of in vivomodels where the Pol I regulatory
components are selectively manipulated to determine the
impact on the pathways controlling skeletal muscle
growth.
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